Clinical Trials: Multiple Myelomas

California

Duarte; City of Hope
Protocol H6Q-MC-S022 A Phase Ib Pharmacokinetic-Pharmacodynamic-Pharmacogenomic Study of Enzastaurin in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Duarte; City of Hope
An Open Label, Single Arm, Phase 2 Study of Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma

Duarte; City of Hope
CALGB 100104/ECOG 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

Duarte; City of Hope
A Phase 1 Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multipe Myeloma

Duarte; City of Hope
SWOG S0434: A Phase II Trial of Bay 43-9006 (Sorafenib) (NSC-724772) in Patients with Relapsing or Resistant Multiple Myeloma

Duarte; City of Hope
A Phase II Study or Oral LBH589 in Adult Patients with Mutiple Myeloma Who Have Received at Least Two Prior Lines of Therapy and Whose Disease is Refractory to the Most Recent Line of Therapy

Duarte; City of Hope
Tandem High-Dose Therapy with Melphalan and Total Marrow Irradiation (TMI) with Peripheral Blood Progenitor Cell Support and Dexamethasone and Thalidomide Maintenance in Multiple Myeloma: A Phase I/II Trial

Duarte; City of Hope
Multiple Myeloma Research Consortium Inc. Ancillary Tissue Collection Study

Duarte; City of Hope
A Phase II Multicenter Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Subjects with Relapsed or Refractory Multiple Myeloma

Duarte; City of Hope
An Open Label Phase I/II Study of Safety and Efficacy of Perifosine and Bortezomib with or without Dexamethasone for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Previously Treated with Bortezomib

La Jolla; Scripps Clinic Medical Group
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Florida

Lecanto; Cancer and Blood Disease Center
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Georgia

Various Cities; Research Center
Multiple Myeloma Study CLBH589B2206

Illinois

Chicago; University of Chicago
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Maryland

Bethesda; Center for Cancer and Blood Disorders
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Missouri

Jefferson City; Capitol Comprehensive Cancer Care Clinic
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

New Jersey

Various Cities; Research Center
Multiple Myeloma Study CLBH589B2207

New York

Buffalo; Roswell Park Cancer Institute
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Lake Success; Biomedical Research Alliance of New York
Relapsed or Refractory Multiple Myeloma - Adults

New York; Columbia-Presbyterian Medical Center
Study of the use of peripheral blood stem cells for allogeneic transplantation (PBSCT) in patients with advanced hematological malignancies at increased risk of relapse or transplant-related mortality

New York; Columbia-Presbyterian Medical Center
Study of donor leukocyte infusions in patients with recurrent or persistent hematological malignancies after allogeneic bone marrow transplantation.

New York; Columbia-Presbyterian Medical Center
Study of standard chemotherapy and radiotherapy before allogeneic stem cell transplantation

New York; Columbia University Medical Center
Myeloma Specimen Repository Protocol, Ancillary.

New York; Columbia University Medical Center
Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Newly Diagnosed Multiple Myeloma.

New York; Columbia University Medical Center
Phase I/II Study of Liposomal Doxorubicin (Doxil®)/ Melphalan/ Bortezomib (Velcade®) in Relapsed/Refractory Multiple Myeloma

Various Cities; Research Center
Multiple Myeloma Study CLBH589B2206

South Carolina

Charleston; Charleston Hematology Oncology
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Texas

Houston; S. R. Burzynski Clinic
Phase II Study Of Antineoplatons A10 And AS2-1 In Patients With Multiple Myeloma

Virginia

Charlottesville; University of Virginia
Adults with Multiple Myeloma Sought for Research Study.

International

Salzburg, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Wien, Austria; Research Site:
A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Calgary, Alberta, Canada; Tom Baker Cancer Center
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Edmonton, Alberta, Canada; Cross Cancer Institute
A phase 2, randomized study of mapatumumab (TRM-1 [HGS1012], a fully human monoclonal antibody to TRAIL-R1) in combination with bortezomib (Velcade®) or bortezomib alone in patients with relapsed or refractory multiple myeloma.

Ansbach, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Aschaffenburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Augsburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Berlin, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Bochum, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Bremen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Duisburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Erlangen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Essen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Esslingen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Frankfurt Am Main, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Freising, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Göttingen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Greifswald, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Güstrow, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Gütersloh, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Halle, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Hamburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Hamm, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Hannover, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Herne, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Hof, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Jena, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Karlsruhe, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Kassel, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Koblenz, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Köln, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Krefeld, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Leer, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Leipzig, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Lübeck, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Ludwigshafen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Magdeburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Mayen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Minden, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Mörs, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Mülheim, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

München, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Münster, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Neumünster, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Offenbach, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Offenburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Oldenburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Stuttgart, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Tübingen, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Weiden, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Wiesbaden, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Würzburg, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Zwickau, Germany; Research Site:
COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma